Prospective randomized comparison of ranitidine bismuth citrate (RBC) versus colloidal bismuth subcitrate (denol)-based triple therapy for the treatment of H. pylori infection

1998 ◽  
Vol 114 ◽  
pp. A190
Author(s):  
NNS Kung ◽  
JY Sung ◽  
WF Yuen ◽  
TH Li ◽  
PW Ng ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Colloidal Bismuth Subcitrate ◽  
Bismuth Citrate ◽  
Bismuth Subcitrate ◽  
H Pylori ◽  
Colloidal Bismuth

scholarly journals Bismuth-Based Triple Therapy with Bismuth Subcitrate, Metronidazole and Tetracycline in the Eradication ofHelicobacter pylori: A Randomised, Placebo Controlled, Double-Blind Study

2000 ◽  
Vol 14 (7) ◽  
pp. 599-602 ◽  
Author(s):  
Sander Veldhuyzen van Zanten ◽  
Alain Farley ◽  
Norman Marcon ◽  
Raymond Lahaie ◽  
André Archambault ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Previous Attempt ◽  
Double Blind Study ◽  
Double Blind ◽  
Colloidal Bismuth Subcitrate ◽  
Intention To Treat ◽  
First Line Therapy ◽  
Bismuth Subcitrate ◽  
H Pylori ◽  
Colloidal Bismuth

OBJECTIVE: To determine the rate ofHelicobacter pylorieradication following bismuth-based triple therapy with colloidal bismuth subcitrate, tetracycline hydrochloride and metronidazole.PATIENTS AND METHODS: One hundred and eleven patients were randomly assigned, in a two to one ratio, to colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid (Gastrostat), or matching placebo tablets and capsules for 14 days. Presence or absence ofH pyloriwas documented by histology at entry and at least 28 days after treatment. Patients had dyspeptic symptoms with or without a history of peptic ulcer. Patients with any previous attempt(s) at eradication ofH pylori, who used bismuth, antibiotics, H2 receptor antagonists or proton pump inhibitors in the previous four weeks were excluded.RESULTS: Fifty-three of 59 (90%) patients on bismuth-based treatment and only one of 35 (3%) on placebo achieved eradication by per protocol analysis. Fifty-three of 65 (82%) patients on bismuth-based treatment achieved eradication, while only two of 34 (5%) achieved eradication on placebo by intention to treat analysis. Eradication rates for bismuth-based treatment across sites ranged from 83% to 100%. Only two patients in the bismuth-based treatment group (4%) and one in the placebo group (3%) discontinued treatment because of adverse events.CONCLUSIONS: Colloidal bismuth subcitrate plus metronidazole plus tetracycline, given in the doses studied for 14 days, is safe and highly effective againstH pyloriinfection and would be appropriate as a first-line therapy for eradication.

Exposure and nephrotoxicity concern of bismuth with the occurrence of autophagy

2018 ◽  
Vol 34 (3) ◽  
pp. 188-199 ◽  
Author(s):  
Yongming Liu ◽  
Chen Shen ◽  
Xihui Zhang ◽  
Huan Yu ◽  
Fujun Wang ◽  
...  
Keyword(s):  
Flame Retardants ◽  
Kidney Injury ◽  
Electronic Industry ◽  
Computed Tomography Imaging ◽  
Tomography Imaging ◽  
Colloidal Bismuth Subcitrate ◽  
Bismuth Citrate ◽  
Bismuth Subcitrate ◽  
Colloidal Bismuth

Metal nanoparticles or metal-based compounds have drawn attention in various fields ranging from industry to medicine because of their unique physicochemical properties. Bismuth (Bi) compounds and nanomaterials have been commonly used in alloys, electronic industry, batteries, and as flame retardants as well as for anti- Helicobacter pylori therapy, while the nanomaterial form has great potential for computed tomography imaging and thermotherapy, both of which will be introduced in this review. Although Bi was used for several decades, there is a lack of detailed information concerning their toxicity and mechanisms on human health. We described the toxicity of Bi on the kidney that seemed to be relatively known by researchers, while the mechanisms remain unclear. Recently, our group has found that Bi compounds, including bismuth nitrate (BN) and Bi nanomaterials, can induce autophagy in kidney cells. We also extended our findings by selecting five Bi compounds, and the results showed that BN, bismuth oxychloride, bismuth citrate, colloidal bismuth subcitrate, and Bi nanomaterials all induced slight cytotoxicity accompanied with autophagy. Although the role of autophagy in Bi-induced cytotoxicity and kidney injury is under investigation by us, autophagy may help with the exploration of the mechanisms of nephrotoxicity by Bi.

scholarly journals Survey of anaemia andHelicobacter pyloriinfection in adolescent girls in Suihua, China and enhancement of iron intervention effects byH. pylorieradication

2011 ◽  
Vol 108 (2) ◽  
pp. 357-362 ◽  
Author(s):  
Wei Xia ◽  
Xin Zhang ◽  
Jiajia Wang ◽  
Caihong Sun ◽  
Lijie Wu
Keyword(s):  
Adolescent Girls ◽  
Intervention Group ◽  
Fe Deficiency ◽  
Control Group ◽  
Colloidal Bismuth Subcitrate ◽  
Bismuth Subcitrate ◽  
H Pylori ◽  
And Control ◽  
The Relationship ◽  
Colloidal Bismuth

In the present study, we investigated the prevalence of anaemia and Fe deficiency anaemia (IDA) and explored the relationship betweenHelicobacter pyloriinfection and IDA in adolescent girls. A total of 1037 adolescent girls from Suihua, China were enrolled. Hb, serum ferritin (SF), serum transferrin receptor (sTfR) and serum IgG antibodies toH. pyloriwere measured. Participants with IDA and co-existingH. pyloriinfection (n80) who had an intake of >25 mg/d of Fe were assigned randomly to the intervention and control groups. Patients in the intervention group were administered a 12-week course of oral EDTA–Na–Fe (60 mg Fe/dose, three times a week) and a 2-week course of colloidal bismuth subcitrate, amoxicillin and metronidazole. Subjects in the control group were administered EDTA–Na–Fe alone. Hb, SF and sTfR were reassessed 3 months after the 12-week regimen ended. Prevalence of anaemia, Fe deficiency (defined as SF < 12·0 μg/l), IDA andH. pyloriinfection in the population of 1037 was 19·5, 40·4, 17·1 and 31·2 %, respectively. The prevalence ofH. pyloriinfection in the IDA group was 46·9 %, while the non-anaemic group had 28·1 % prevalence. A significant increase in Hb and SF and a decrease in sTfR value were found in the intervention group and theH. pylori-negative group. Findings suggest that IDA is still one of the prominent problems in adolescent girls. There is an association betweenH. pyloriinfection and IDA. Treatment ofH. pyloriinfection is associated with a more rapid response to oral Fe therapy.

scholarly journals Effects of In Vitro Antibiotic Resistance on Treatment: Bismuth-Containing Regimens

2000 ◽  
Vol 14 (10) ◽  
pp. 885-889 ◽  
Author(s):  
Naoki Chiba
Keyword(s):  
Antibiotic Resistance ◽  
Triple Therapy ◽  
Eradication Therapy ◽  
Colloidal Bismuth Subcitrate ◽  
Bismuth Citrate ◽  
Bismuth Compounds ◽  
Metronidazole Resistance ◽  
H Pylori

Bismuth compounds remain useful forHelicobacter pylorieradication therapy. These include colloidal bismuth subcitrate (CBS), bismuth subsalicylate (BSS) and, most recently, ranitidine bismuth citrate (RBC). CBS appears to prevent the development of imidazole resistance when coadministered with nitroimidazoles. Traditional triple therapy with bismuth, metronidazole and tetracycline or amoxicillin (BMT/A) only partially overcomes metronidazole resistance. However, the addition of a PPI to bismuth triple therapy largely overcomes established metronidazole resistance if treatment is given for at least one week or more. When RBC rather than PPI is used with clarithromycin, this dual regimen appears to be more effective in preventing the development of secondary clarithromycin resistance. The triple combination of RBC, metronidazole and clarithromycin appears to be effective against metronidazole resistant strains ofH pylori. Thus, overall, there is some evidence that bismuth compounds may prevent the development of antibiotic resistance and that existing antibiotic resistance may at least be partially overcome in vitro and in vivo. With the growing emergence ofH pyloriresistance to metronidazole and clarithromycin, further research to clarify the role of bismuth compounds is required.

Sign in / Sign up

Export Citation Format

Share Document